UK’s first-ever norovirus mRNA vaccine trial launched in Wales
Help to see if we can protect people against symptoms caused by the norovirus stomach bug with an investigational mRNA vaccine.
The North Wales Clinical Research Facility (NWCRF) is looking for participants for the Nova 301 Trial. This trial will see if an investigational vaccine can protect people 60 years of age or older against symptoms caused by the norovirus stomach bug.
About the norovirus stomach bug
Norovirus is one of the most common stomach bugs in the UK. It can spread easily and most cases are often in care homes and schools. The norovirus stomach bug can cause many unpleasant symptoms like nausea, vomiting, and diarrhoea.
About the Nova 301 Trial
The Nova 301 Trial will see if an investigational vaccine (a vaccine that is being studied) may be able to prevent symptoms caused by the norovirus stomach bug from developing in people 18 years of age or older. The investigational vaccine in this clinical trial is called mRNA-1403. You cannot catch norovirus by having this investigational vaccine.
Who can join?
This clinical trial is looking for participants. To join, you must:
What to expect
Your participation in the Nova 301 Trial will last up to 25 months.
Moderna will reimburse participants for their trial-related time and expenses (for example, travel), and the clinical trial team are on hand to support everyone who takes part in the trial.
Diseases do not discriminate — and neither should clinical trials.
Moderna is committed to researching mRNA-based vaccines and therapies to bring better health and living to people of all ages, sexes and backgrounds.
Contact the clinical trial team today
Call 03000 847547 or email BCU.NWCRFParticipant@wales.nhs.uk, or visit www.nova301trialuk.com to find out more about joining the Nova 301 Trial.